Product Description
AL1211 is a glucosylceramide synthase (GCS) inhibitor with unique and superior properties to other GCS inhibitors currently approved or in development. AL1211 is more potent and has a better off-target activity profile than other GCS inhibitors. AL1211 also has excellent penetration into the tissues that are affected in Fabry disease like heart and kidney. Importantly, AL1211 has low brain penetration, which maximizes the treatment of peripheral organs without concern for negative effects in the brain. (Sourced from: https://acelinktherapeutics.com/al1211/)
Mechanisms of Action: GCS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AceLink Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Fabry Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|